Indian litigation seeks to close Ranbaxy plants
Public interest litigation also asks for probe of officials in India.
An Indian lawyer has filed a lawsuit asking India’s Supreme Court to shut down the two Ranbaxy Laboratories manufacturing plants named in the U.S. charges and for the court to order the Central Bureau of Investigation (CBI) to investigate the U.S. case. It also presses the court to start criminal proceedings against executives who were at the company when the fraud was executed, according to The Economic Times. The suit was filed by lawyer Manoharlal Sharma as a public interest litigation. A PIL can be brought by any citizen in India. The lawsuit pointed out that Ranbaxy drugs banned by the U.S. continued to be sold in the Indian market.
«It is not a tale of cutting corners or lax manufacturing practices, but one of outright fraud, in which the company knowingly sold substandard drugs around the world, including in India, Africa and the U.S. while working to deceive regulators," the PIL reads.
Ranbaxy’s problems were brought to U.S. officials by a whistleblower back in 2008, and the regulatory investigation and actions escalated over a
Ranbaxy has made a public statement assuring the public that «all Ranbaxy products currently in the Indian and global markets are safe and effective," and the government has come out with a statement defending the domestic